MD2B: Solid Tumors

Brain Tumors
Cervical Cancer
Cervical Cancer: HPV Vaccines
Colorectal Cancer
Head and Neck Malignancies
Lung Cancer
MD2B - Breast Cancer
Pancreatic Cancer
Prostate Cancer
Renal Cell Carcinoma
Sarcomas - Bone And Soft Tissue Malignancies
Skin Cancer
Wilm's Tumor

Longer Course of Imatinib Better in Trial for GI Stromal Tumor

Mar 28, 2012 - A longer course of imatinib (36 months versus 12 months) significantly improves recurrence-free survival and overall survival in postoperative patients at high risk for recurrence of gastrointestinal stromal tumor, according to a study published in the March 28 issue of the Journal of the American Medical Association.

OncoLink Treatment Binder

Select the side effects and forms for your patient's treatment binder

Learn More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More